Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 206,246
  • Shares Outstanding, K 47,196
  • Annual Sales, $ 1,990 K
  • Annual Income, $ -59,980 K
  • 60-Month Beta 2.18
  • Price/Sales 105.54
  • Price/Cash Flow N/A
  • Price/Book 23.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.50
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -7.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +13.25%
on 08/28/19
4.85 -11.03%
on 08/23/19
-0.16 (-3.68%)
since 08/16/19
3-Month
3.81 +13.25%
on 08/28/19
5.55 -22.25%
on 07/15/19
+0.11 (+2.49%)
since 06/17/19
52-Week
2.35 +83.62%
on 05/21/19
7.31 -40.97%
on 10/01/18
-1.82 (-29.72%)
since 09/17/18

Most Recent Stories

More News
Ocular Therapeutix(TM) to Present at the 2019 Wells Fargo Healthcare Conference

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced...

WFC : 48.76 (-0.45%)
OCUL : 4.31 (-1.37%)
SmarTrend Watching for Potential Rebound in Shares of Ocular Therapeut After 7.90% Loss

Ocular Therapeut (NASDAQ:OCUL) traded in a range yesterday that spanned from a low of $4.08 to a high of $4.47. Yesterday, the shares fell 7.9%, which took the trading range below the 3-day low of $4.41...

OCUL : 4.31 (-1.37%)
Ocular Drug Delivery Technology Market by Growth 2019 - Technological Strategies, Business Advancements and Top-Vendor Landscape 2028

The report attempts to offer high-quality and accurate analysis of the Global Ocular Drug Delivery Technology Market, keeping in view market forecasts, competitive intelligence, and technological risks...

VRX.TO : 30.80 (-3.33%)
ALIM : 0.41 (-2.38%)
CLSD : 0.75 (-8.54%)
AGN : 166.10 (+0.33%)
NVS : 86.53 (+0.45%)
PFE : 36.50 (-0.90%)
OCUL : 4.31 (-1.37%)
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -35.71% and -35.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

OCUL : 4.31 (-1.37%)
Ocular Therapeutix: 2Q Earnings Snapshot

BEDFORD, Mass. (AP) _ Ocular Therapeutix Inc. (OCUL) on Wednesday reported a loss of $24.5 million in its second quarter.

OCUL : 4.31 (-1.37%)
Ocular Therapeutix(TM) Reports Second Quarter 2019 Financial Results and Business Update

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.31 (-1.37%)
Ocular Therapeutix(TM) To Report Second Quarter 2019 Financial Results

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.31 (-1.37%)
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

OCUL : 4.31 (-1.37%)
Glaucoma Drugs Market 2019 Top Key Players are Aerie Pharmaceuticals, Allergan plc, Bausch & Lomb Incorporated, Inotek Pharmaceuticals, Merck & Co. Inc., Pfizer Inc., Merck & Co., and Forecast to 2025

: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?.Rise in prevalence of eye disorders such as Presbyopia, Macular Degeneration and Diabetic Retinopathy in the aging population...

VRX.TO : 30.80 (-3.33%)
OCAT : 8.47 (+0.12%)
AERI : 22.79 (-4.40%)
SNPHF : 16.8000 (+1.69%)
MRK : 82.51 (+0.59%)
AGN : 166.10 (+0.33%)
NVS : 86.53 (+0.45%)
PFE : 36.50 (-0.90%)
OCUL : 4.31 (-1.37%)
PRGO : 55.72 (-1.73%)
OHRP : 5.39 (+30.19%)
ITEK : 3.04 (-5.00%)
SCMP : 18.05 (+0.28%)
NMUS : 0.6500 (-9.52%)
TEVA : 7.92 (-1.49%)
Ocular Therapeutix(TM) Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA(R) (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services

Ocular Therapeutix(TM), Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...

OCUL : 4.31 (-1.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade OCUL with:

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

2nd Resistance Point 4.70
1st Resistance Point 4.54
Last Price 4.31
1st Support Level 4.28
2nd Support Level 4.18

See More

52-Week High 7.31
Fibonacci 61.8% 5.42
Fibonacci 50% 4.83
Last Price 4.31
Fibonacci 38.2% 4.24
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar